从急性荨麻疹进展为慢性荨麻疹:系统综述
进展率报告为5.8%至36.0%,受随访时长和结局定义影响。未发现一致的临床或实验室标志物与慢性化相关,急性期使用全身糖皮质激素未降低进展风险。
要点
- 急性荨麻疹进展率5.8%–36.0%,受随访时长和结局定义影响。
- 疾病严重度、血管性水肿、过敏致敏等与慢性化关联不一致。
- 急性期全身糖皮质激素使用未降低进展为慢性荨麻疹的风险。
核心结论
- 无单一临床或实验室标志物与急性荨麻疹进展为慢性荨麻疹一致相关。
- 当前证据不支持仅为预防慢性化而在急性期采用激进治疗策略。
- 需设计良好的多中心前瞻性研究,采用标准化结局定义和更长随访。
研究设计与样本
- 系统检索MEDLINE、Embase和Web of Science从建库至2025年12月31日的英文研究。
- 纳入评估急性荨麻疹患者慢性化相关因素的观察性研究。
- 两名评审独立筛选、提取数据,采用改良Newcastle-Ottawa量表评估偏倚风险,GRADE评估证据确定性。
- 因异质性采用定性综合。
主要发现
- 报告的进展率范围为5.8%至36.0%,受随访时长和结局定义影响。
- 三级中心较高进展率可能反映选择偏倚。
- 疾病严重度、血管性水肿、过敏致敏和特应性状态等临床因素与慢性化关联不一致。
- 总免疫球蛋白E、嗜酸性粒细胞计数、全身炎症指数(包括中性粒细胞与淋巴细胞比值和全身免疫炎症指数)及自身抗体谱等实验室标志物与进展无重复性关联。
- 急性期使用全身糖皮质激素等治疗相关因素与进展风险降低无关。
关键数值与推荐
- 进展率范围为5.8%至36.0%(急性荨麻疹患者,受随访时长和结局定义影响)。
- 证据质量受方法学异质性、随访较短和中至高偏倚风险限制。
临床怎么用
- 对急性荨麻疹患者应进行仔细临床评估和结构化随访。
- 不应仅以预防慢性化为目的在急性期积极使用全身糖皮质激素。
- 新兴炎症和免疫学参数数据可能有助于识别更高风险亚组。
局限性
- 方法学异质性大,证据质量受限。
- 随访时间短。
- 偏倚风险为中至高度。
- 三级中心进展率较高可能反映选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Progression from acute urticaria (AU) to chronic urticaria (CU) occurs in a subset of patients, but consistent factors associated with progression remain unclear. Identifying patients at risk could inform follow-up strategies and therapeutic decisions; however, evidence on prognostic factors is heterogeneous and uncertain. OBJECTIVE: To systematically review clinical, laboratory, and treatment-related factors associated with progression from AU to CU. EVIDENCE REVIEW: A systematic search of MEDLINE, Embase, and Web of Science was conducted for English-language studies from database inception to December 31, 2025. Observational studies evaluating factors associated with chronicity in patients with AU were included. Paired reviewers independently screened studies, extracted data, and assessed risk of bias using an adapted Newcastle-Ottawa Scale and certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Due to heterogeneity, findings were synthesized qualitatively. FINDINGS: Sixteen studies (52 564 total patients; sample size range, 57 to 49 129 patients) were included. Reported progression rates ranged from 5.8% to 36.0%, influenced by follow-up duration and outcome definitions, with higher rates potentially reflecting selection bias in tertiary centers. Clinical factors, such as disease severity, angioedema, allergic sensitization, and atopic status, showed inconsistent associations with chronicity. Laboratory markers, such as total immunoglobulin E, eosinophil counts, systemic inflammatory indices (including the neutrophil-to-lymphocyte ratio and systemic immune-inflammation index), and autoantibody profile, were not reproducibly associated with progression. Treatment-related factors, including the use of systemic corticosteroids during the acute phase, were not associated with reduced risk of progression. Overall, evidence quality was limited by methodologic heterogeneity, short follow-up, and moderate to high risk of bias. CONCLUSIONS AND RELEVANCE: This systematic review found that no single clinical or laboratory marker was consistently associated with progression from AU to CU, and current evidence does not support the use of aggressive treatment strategies during the acute phase solely to prevent chronicity. Careful clinical evaluation and structured follow-up remain essential, and emerging data on inflammatory and immunologic parameters may help identify subgroups at higher risk. These findings underscore the need for well-designed multicenter prospective studies with standardized outcome definitions and longer follow-up.
引用
- Gómez de la Fuente E, Ortiz de Frutos FJ, Álvarez-Díaz N, et al. Progression From Acute to Chronic Urticaria: A Systematic Review. JAMA Dermatol. 2026. PMID: 42340685. doi:10.1001/jamadermatol.2026.1901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。